Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited naming Lorraine Clifford-Lee .
Filed returns
17
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2026 | Hanover Media Strategy Limited | Transport | The role of the car rental sector in supporting Ireland’s tourism economy, regional connectivity and airport operations, and issues facing the tourism and car rental sectors arising from the proposed EU Clean Corporate… (Public policy or programme) | 21 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Transport | The taxi supply shortage in Ireland and the need to increase licensed taxi driver and vehicle supply to support the urban, rural and night-time economies. (Public policy or programme) | 14 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | AV Room Briefing Event to discuss a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) | 41 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Transport | Correspondence and meetings regarding the Taxi Supply Shortage (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Invitation to a roundtable discussion on the challenges and pressures posed by influenza on the Irish health system, with a particular focus on the over 65s population. (Public policy or programme) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Chronic kidney disease in Ireland: recommendations to improve health outcomes for chronic kidney disease patients and reduce healthcare costs. (Matters involving public funds) | 15 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 23 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 10 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | The landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Ireland's readiness for the rollout of radioligand therapy (Public policy or programme) | 12 | On lobbying.ie |
| Jan–Apr 2023 | Hanover Media Strategy Limited | Health | Rare Disease Policy (Legislation) | 17 | On lobbying.ie |
| Sep–Dec 2022 | Hanover Media Strategy Limited | Health | Request for a meeting to discuss the landscape for innovative and precision medicines in Ireland. (Public policy or programme) | 18 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Update on AstraZeneca sponsored roundtable outcomes held for Chronic Obstructive Pulmonary Disease (Public policy or programme) | 14 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Creation of national policy with regard to Orphan Medicinal Products (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 14 | 82.4% | |
| Transport | 3 | 17.6% |